Akero Therapeutics, Inc. (AKRO)

19,66 -0,05 (-0,25%) Alla chiusura: 04:00PM EDT

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://akerotx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 55

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Andrew Cheng M.D., Ph.D.	President, CEO & Director	1,04M	15,28M	1967
Dr. Jonathan M. Young J.D., Ph.D.	Co-Founder, Executive VP, COO & Secretary	672,35k	584,34k	1970
Dr. Timothy Rolph	Co-Founder & Chief Scientific Officer	722,32k	2,16M	1954
Mr. William R. White J.D.	Executive VP, CFO, Treasurer & Head of Corporate Development	678,06k	839,84k	1973
Ms. Catriona Yale	Executive VP & Chief Development Officer	678,06k	458,9k	1972
Mr. Scott A. Gangloff	Chief Technology Officer	N/D	N/D	1974
Mr. Patrick Lamy	Senior Vice President of Commercial Strategy	N/D	N/D	1973
Mr. John J. Schembri	VP of Finance & Controller	N/D	N/D	1962

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Akero Therapeutics, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.